The aetiology of pouchitis in patients with inflammatory bowel disease

被引:2
|
作者
Alenzi, Maram [1 ]
Schildkraut, Tamar [2 ]
Hartley, Imogen [2 ,3 ]
Badiani, Sarit [4 ]
Ding, Nik Sheng [2 ,3 ]
Rao, Vikram [5 ]
Segal, Jonathan P. [3 ,6 ]
机构
[1] Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02115 USA
[2] St Vincents Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[3] Royal Melbourne Hosp, Dept Gastroenterol, Parkville, Vic, Australia
[4] Royal North Shore Hosp, Dept Surg, St Leonards, NSW, Australia
[5] Western Hlth, Dept Gen Med, Footscray, Vic, Australia
[6] Univ Melbourne, Dept Med, Parkville, Vic, Australia
关键词
IBD; pouchitis; ulcerative colitis; ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; ULCERATIVE-COLITIS PATIENTS; FAMILIAL ADENOMATOUS POLYPOSIS; SULFATE-REDUCING BACTERIA; IL-1 RECEPTOR ANTAGONIST; ILEAL-POUCH; ANAL ANASTOMOSIS; RESTORATIVE PROCTOCOLECTOMY; HYDROGEN-SULFIDE; CROHNS-DISEASE;
D O I
10.1177/17562848241249449
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Restorative proctocolectomy with ileal pouch-anal anastomosis is a treatment option for patients with refractory ulcerative colitis. Pouchitis is the most common complication, representing a spectrum of diseases ranging from acute antibiotic-responsive type to chronic antibiotic-refractory. Early accurate diagnosis using a combined assessment of symptoms, endoscopy and histology is important for both treatment and prognostication. Most patients respond well to antibiotic therapy; however, management of chronic antibiotic-refractory pouchitis remains a challenge, and treatment options are based on small studies. Pouchitis is thought to be driven by the interaction between genetics, the immune system and the environment but as yet a causal relationship has yet to be identified. Further longitudinal assessment of the pouch integrating new technologies may help us understand the factors driving pouchitis. This review outlines the currently understood risk factors and aetiology of pouchitis.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Multiparity in Inflammatory Bowel Disease Patients
    Naik, Amar S.
    Zadvornova, Yelena
    Stein, Daniel J.
    Perera, Lilani P.
    Saeian, Kia
    Venu, Nanda
    GASTROENTEROLOGY, 2012, 142 (05) : S267 - S268
  • [42] Infections in patients with inflammatory bowel disease
    Fornaro, Rosario
    Caratto, Elisa
    Caratto, Michela
    Mascherini, Matteo
    Dibitonto, Luca
    Costa, Riccardo
    Sticchi, Camilla
    Frascio, Marco
    ANNALI ITALIANI DI CHIRURGIA, 2020, 91 (06) : 627 - 632
  • [43] Immunizations in Patients with Inflammatory Bowel Disease
    Lu, Ying
    Jacobson, Denise
    Bousvaros, Athos
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (09) : 1417 - 1423
  • [44] Communicating with patients with inflammatory bowel disease
    Husain, A
    Triadafilopoulos, G
    INFLAMMATORY BOWEL DISEASES, 2004, 10 (04) : 444 - 450
  • [45] Supporting patients with inflammatory bowel disease
    Dalibon, Pierre
    ACTUALITES PHARMACEUTIQUES, 2015, 54 (545): : 35 - +
  • [46] Infections in Patients with inflammatory Bowel Disease
    不详
    COLOPROCTOLOGY, 2019, 41 (04) : 241 - 241
  • [47] Inflammatory bowel disease in pediatric patients
    Marx, G
    Seidman, EG
    CURRENT OPINION IN GASTROENTEROLOGY, 1999, 15 (04) : 322 - 325
  • [48] 'Osteoporosis in patients with inflammatory bowel disease
    Bernstein, CN
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (02) : 152 - 156
  • [49] Elderly patients and inflammatory bowel disease
    Danielle Nimmons
    Jimmy K Limdi
    World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7 (01) : 51 - 65
  • [50] Inflammatory bowel disease in celiac patients
    Masachs, M.
    Casellas, F.
    Malagelada, J. R.
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2007, 99 (08) : 446 - 450